KLF4 and neoplasm: There are several mechanisms of KLF4 as an oncogene: (i) inhibitor of Wnt/beta – catenin pathway: Yu [48] has found that KLF4 could be combined with the β-catenin, and then inhibited beta-catenin getting into the nucleus and binding with T cell factor, leading to the suppression of the downstream target gene of Wnt/beta-catenin pathway; (ii) regulation of the Notch pathway to inhibit tumour development: Ghaleb [49] found that Klf4 was the downstream target gene of the Notch pathway, and its transcription activity was inhibited by Notch.